- LOGIN
- MemberShip
- 2026-04-10 08:38:10
- Company
- Roche and Korea BIO offers opportunity to domestic companies
- by Hwang, Jin-joon Apr 11, 2023 06:08am
- KoreaBIO and Roche are hosting an open innovation event(Pic: KoreaBIO) The Korea Biotechnology Industry Organization will be providing opportunities for technology transfer and overseas expansion of domestic biopharmaceutical companies. For this purpose, Korea Bio plans to first cooperate with the multinational pharmaceutical company Roche. According to industry sources on the 10th, Korea BIO is planning to hold a ‘Korea BIO x Roche Partnering’ open innovation event on the 9th of next month. The event will be held on and offline at Roche Korea’s head office in Gangnam, Seoul, and be attended by groups wishing to partner with Roche. The event will offer one-on-one meetings between global pharmaceutical companies and domestic biopharmaceutical companies. Korea BIO planned the event to provide opportunities for domestic pharmaceutical and biohealth companies to receive a diagnosis on their commercialization potential for technology transfer and overseas expansion, etc. Domestic pharmaceutical and biohealth companies wishing to engage in technology transfer and joint research with Roche can submit an application, and prepare nonconfidential company introduction materials, personal information consent form, and company introduction material consent form to Korea Bio by the 24th of this month. The company introduction materials should only include only publicly available data. When the domestic pharmaceutical and biohealth companies submit the required documents, Roche Asia Partnering will select companies after review. Select companies will have on/offline meeting opportunities with Roche, and receive feedback related to the contents discussed. Then, a select few that wish to partner with Roche will receive the opportunity to have face-to-face meetings at Roche headquarters, global branches, and subsidiary research institutes. As collaboration areas, Roche suggested immunology, oncology, neurological disorders, research and development technology, personalized digital healthcare, rare diseases, and infectious diseases. If approved, the collaboration will be carried out with its Genentech Research Center, Roche Innovation Center Basel, Roche’s Shanghai Innovation Center, Global Product Development Department, and Product Strategy Department, etc. The industry believes that Korea BIO's open innovation project will be an opportunity for domestic companies to receive feedback from multinational pharmaceutical companies on their direction of pipeline research, further required research, and the marketability of their candidate substances. Starting with Bayer in 2021, Korea BIO had held open innovation partnering events with Boehringer Ingelheim, Novartis, French Healthcare Club, and CJ in the same year.
- Policy
- 3 combination DM drug is cheaper than the 2 combi
- by Lee, Tak-Sun Apr 10, 2023 05:53am
- 2-drug combination therapy should also be provided with reimbursement standards From this month, as it is applied to the three-drug combination therapy of SGLT2 inhibitors, prescriptions for the existing two-drug therapy (SGLT2i + DPP4i) are expected to decrease significantly. The HIRA said on the 5th through a Q&A related to the reimbursement standards for diabetes medications that will change from this month, “The two-drug combination therapy of a combination of a DPP-4 inhibitor and an SGLT-2 inhibitor is only one type of combination within the scope of approval, as is the case at present. You can apply it with a burden,” he explained. DPP4i+SGLT2i that are currently within the scope of approval are Januvia and Forxiga. The amount the patient will pay is 987 won, which is the sum of 734 won (Forxiga, fully paid by the patient) and 253 won (Januvia, 30% of 846 won). If Metformin is included in the prescription, the drug cost will decrease. This is because from this month, regardless of the ingredients, benefits will be applied to the combined use of met+DPP4i+SGLT2i. This is because if Forxiga 10mg + Januvia 100mg plus Metformin 500mg (highest price 119 won), which is taken daily, the patient's co-payment is only 509 won because 30% is applied. From the patient's point of view, the cost of three drugs has become cheaper than the cost of two drugs. Accordingly, it is analyzed that there is a high possibility that the medical field will prescribe a 3-drug containing metformin instead of an expensive 2-drug. Some experts are concerned that prescriptions for metformin will increase even for patients who do not need to take metformin, and social costs may only increase if prescribed Metformin is not accepted. There is also an opinion of regret that the DPP4i + SGLT2i two-drug regimen is not provided in this reimbursement standard. However, as the reimbursement review for the two-drug combinations is underway, some say that the reimbursement criteria for the two-drug regimen will be established sooner or later.
- Policy
- Reimb review for Pompe disease drug Nexviazyme underway
- by Lee, Tak-Sun Apr 10, 2023 05:53am
- Reimbursement review is underway in Korea for Nexviazyme Inj (avalglucosidase alfa-ngpt), Sanofi’s Pompe disease drug that had been approved by the Ministry of Food and Drug Safety on the 29th. Nexviazyme is the first biobetter among rare disease drugs to be approved in Korea. According to industry sources on the 7th, the Health Insurance Review and Assessment Service started the reimbursement review for Nexviazyme and requested the Ministry of Food and Drug Safety to confirm the drug’s Target Product Profile. Nexviazyme is regarded an upgraded version of the company's Myozyme. The MFDS has been approving products with improved safety, efficacy, and use over existing approved biodrugs or those that were recognized for their progressive technology, as biobetters. Nexviazyme is the first drug among rare disease drugs to obtain marketing authorization as a biobetter drug. Pompe’s disease is caused by a genetic deficiency or dysfunction of the lysosomal enzyme acid alpha-glucosidase (GAA). When left untreated, it may lead to muscle damage, respiratory failure, movement disorders, and even premature death. The company has implemented innovative technology to increase the amount of mannose-6-phosphate (M6P), which plays a major role in the drug's cellular enzyme uptake, in Nexviazyme by 15 times compared with Myozyme. The company added, the increase in M6P also improves immunogenicity and provides safety benefits. Myozyme is currently reimbursed at KRW 653,000 per vial. In 2021, USD 7.7 million's worth of Myozyme was imported to Korea.
- Company
- Two types of RET-targeted anti-cancer drugs for minority pts
- by Eo, Yun-Ho Apr 10, 2023 05:52am
- It does not seem easy to enter the insurance coverage of RET-targeted anti-cancer drugs targeting a very small number of patients. According to related industries, Retevmo of Lilly Korea failed to pass the HIRA held on the 6th, and Roche Korea's Gavreto submitted an application for benefits last year, but it has not yet been presented to the Cancer Disease Review Committee, and discussions are slow. However, in the case of Retevmo, as the decision to re-discuss was made, there is room for hope. Although the application for Gavreto was delayed compared to Retevmo, there is no news about it, despite the strong tendency of the government to evaluate drugs with the same mechanism. Retevmo and Gavreto both obtained FDA approval in March. Retevmo was a bit early for global first permission. Retevmo obtained marketing approval from the US FDA in May last year and Gavreto in September last year. Retevmo was approved for two indications of non-small cell lung cancer and thyroid cancer, and for indications of Gavreto, thyroid cancer was added in December of the same year after approval as a lung cancer treatment. Since these drugs suppress not only the primary mutation of the RET gene but also the secondary mutation that causes resistance to chemotherapy, it was expected that they would be able to solve the unmet demand in various types of cancer, but they are experiencing difficulties in the insurance coverage process. Cho Byung-cheol, a professor at the Lung Cancer Center at Yonsei Cancer Center, said, "Until now, there were no chemotherapy options for patients with RET gene mutation cancer, so we had no choice but to undergo chemotherapy in the same way as general cancer patients. It can be an alternative for patients who have had difficulties with relatively low anti-cancer toxicity.” Meanwhile, in the LIBRETTO-001 clinical trial, Retevmo recorded a response rate of 64% in non-small cell lung cancer patients who had previously received platinum chemotherapy and an 85% response rate in the newly diagnosed group. Gavreto significantly reduced tumors by 58.8% in non-small cell lung cancer patients who had previously received chemotherapy in the Arrow trial. In patients diagnosed for the first time, the response rate was 72%.
- Policy
- Only a few cold drugs will be subject to PVA negotiations
- by Lee, Tak-Sun Apr 10, 2023 05:52am
- The number of drugs subject to negotiations under the Price-Volume Agreement (PVA) system among cold medicines and antibiotics whose usage increased explosively with the rise in the number of confirmed COVID-19 patients, is expected to be small. When the National Health Insurance Service applied the correction plan it had devised after collecting industry opinion, results showed that little more than 10 items were subject to negotiations. Such results will be applied around the end of April when the government monitors PVA ‘Type C’ drugs. According to industry sources on the 8th, the NHIS corrected the use amount of about 2,600 cold medicines and antibiotics whose use had increased due to COVID-19 and simulated the number of items that will be subject to negotiations. Results showed that the subject drugs were reduced to around 10. The correction was made by comparing each drug’s use amount with the previous year after excluding their usage from a specific month when the number of COVID-19 cases increased explosively. When applying the correction, most of the drugs were not subject to receive negotiations. In other words, their amount of use was similar to the previous year, if not for the COVID-19 crisis. Drugs fall under Type C when claims of products in the same therapeutic class increase by over 60% from the claims amount filed in the previous year, or have increased by over 10% but the increased amount exceeds KRW 5 billion. Items that did not undergo NHIS negotiations on their expected claims amount fall under ‘Type C.' Most of the cold medicines and antibiotics that the correction plan will be applied to fall under PVA ‘Type C.' Therefore, the NHIS plans to apply the final correction plan when monitoring drugs for Type C PVA negotiations. As monitoring is expected to begin at the end of April, the industry expects the correction plan to soon be finalized.
- Company
- It is difficult to secure domestic funding for bio ventures
- by Hwang, Jin-joon Apr 10, 2023 05:51am
- Head of KDDF, Muk Hyun-sang, is presenting major business plans for this year. (Photo: Dailypharm)"It is not easy to change KDDF's funding method. It is possible to raise funds only when investors flock to it, but in order to attract funds from the United States, we are planning an event to invite major US VCs to invest in Korean bio ventures in July. are doing." Muk Hyun-sang, head of KDDF, made this announcement at a press conference held on the 5th at the Korea Chamber of Commerce and Industry's mid-sized conference room in Jung-gu, Seoul to mark the 2nd anniversary of KDDF's launch. Director Muk Hyun-sang explained, "I thought KDDF funds were priming water," and explained, "If you support about 10% of the necessary R&D costs, the company has raised 15 billion won by itself, but it is currently difficult." "It is difficult to increase the amount of money that can be supported by KDDF," he said. "We are looking for a way to get funds from the outside. The US VC invitation event plan is one of the ways to connect financing." KDDF plans to invest a total project cost of 2.1758 trillion won by 2030. The business goals are 60 global technology transfers worth 20 billion won or more, 35 cases worth 100 billion won or more, 4 new drug approvals from the FDA and the EMA, and the creation of one global blockbuster new drug with annual sales of 1 trillion won or more. Director Muk said, “The business carried out by KDDF cannot be seen as a general state-sponsored new drug development project.” there is, and if a company is short of funds, KDDF should create an opportunity to raise funds." KDDF is also planning to carry out 'ADCaptain' to support the ADC project, which is considered a next-generation treatment this year. KDDF plans to prioritize pipelines targeting pancreatic cancer, ovarian cancer, and triple-negative breast cancer among solid cancers and strengthen support through the ADCaptain project. It plans to provide R&D subsidy through investment without equity dilution and support up to 20 million dollars by 2025. From this year to next year, it plans to establish a joint operating committee through cooperation between participating companies and investment companies in the form of a virtual company. A science development advisory committee will also be operated. KDDF plans to select three tasks as leading material development tasks and support 800 million won each for two years. When it enters the development stage after 2024, it plans to establish a corporation and distribute shares. The CEO will be nominated by the company in charge of clinical development. The chairman of the board of directors is appointed by KDDF. R&D funds will be raised through KDDF R&D subsidy, global VC investment, and government fund investment. The required investment is expected to be 24 million dollars. Director Muk said, "It has become KDDF's mission to raise funds. We submitted a budget plan related to new drug development worth 250 billion won to the Abu Dhabi Investment Authority through the Ministry of Strategy and Finance, and we will contact Singapore's Temasek."
- Company
- GemVax’s Alzheimer’s Tx GV1001 receives IND approval
- by Kim, Jung-Ju Apr 07, 2023 05:55am
- On the 4th, GemVax & KAEL announced that it had received investigational new drug (IND) approval for the Phase II trial of its Alzheimer’s treatment candidate, GV1001, in 7 European countries as planned. With its procedures for clinical trial approvals in the 7 European countries complete, the company plans to accelerate the clinical trials in Europe, starting with the initiation of the clinical trial in Spain. A GemVax official said, “With approval complete in 7 European countries, we expect the clinical trials we initiated in Europe to speed up. The global clinical trial of our Alzheimer's disease treatment GV1001 is progressing smoothly in the U.S. and Europe, therefore, we will do our best to achieve significant clinical results." The company plans to enroll a total of 185 patients, 77 from the US and 108 from Europe in the global clinical trial for GV1001. The company explained that the first patient was registered in the US last October and that a total of six patients have been registered so far. The clinical trial will evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) subcutaneously as a treatment for mild-to-moderate Alzheimer's disease (AD) for 53 weeks (12 months). In addition, GemVax has also received approval from Korea’s Ministry of Food and Drug Safety to conduct a clinical trial on GV1001 as a treatment for progressive supranuclear palsy (PSP). This is expected to become the first clinical trial conducted in Korea for PSP. As GV1001 is being studied for PSP in addition to the Alzheimer's disease clinical trials that are being actively conducted in Korea and abroad, GV1001’s scope is expected to expand further to cover a range of neurodegenerative diseases.
- Company
- The dilemma of price cuts for Lipiodol and Fattiodol
- by Nho, Byung Chul Apr 07, 2023 05:55am
- There are many opinions of concern that the two items of X-ray contrast medium registered as essential medicines may fall into a situation where supply is not possible. According to the industry, price cuts are scheduled for Lipiodol and Fattiodol on the 1st of next month, and the price of raw materials for these products is high. The original product, Guerbet Fattiodol Ultra, obtained domestic approval in 1998 and was recognized for its insurance price of 52,560 won in 2016. Afterward, the pharmaceutical company filed an application for drug price adjustment with the health authorities in 2018, citing lower margins compared to cost, and was found to have led to a drug price increase of 190,000 won, a 261% increase from the previous one. Lipiodol is 189,224 won in January 2022, 133,000 won in September 2022, 189,224 won in September 2022, and 133,000 won in January 2023. The drug price is scheduled to be reduced to 1,745 won. The situation is equally bad for Dongkuk Fattiodol, the only generic drug in the market approved in 2020. At the time of registration, the additional drug price was recognized and 59.5% (113,050 won) of 190,000 won was recognized, but the drug price is scheduled to be reduced to 101,745 won on the 1st of next month. Application for drug price adjustment is virtually the only way to raise or preserve drug prices, but it cannot be used because there are alternative drugs between Lipiodol and Fattiodol. If two pharmaceutical companies simultaneously stop supplying drugs due to lower margins following drug price cuts, a supply-demand crisis is expected. An industry insider said, "Estimating the cost of essential medicines and resolving the dynamics of drug price cuts is a mid-to-long-term task that the health authorities must solve." The main component of Lipiodol is Ethyl Esters Of The Iodised Fatty Acids Of Poppyseed Oil, which is used for lymphography, salivary gland imaging, carotid artery chemoembolization for liver cancer, and hysterosalpingography. Last year, Lipiodol and Fattiodol last year's performance were about 2.8 billion won and 36 million won, respectively.
- Company
- Rise of new drugs... subject of NA and public petitions
- by Eo, Yun-Ho Apr 07, 2023 05:54am
- Specific product names of new drugs are being mentioned at the National Assembly audit and public petitions calling for the application of reimbursement for specific drugs have gathered 50,000 consents. Such activities, which would not have happened 5 years ago, are actually arising in Korea. The emergence of government affairs (GA) and patient advocacy (PA) managers are not irrelevant to the rise of such new drug issues and are more fundamentally related to the industry’s entry into an era of high-priced new drugs. ◆Awakening of the patients and rising public interest=" Please doctor, you are our only hope. Please save me.’ Times have changed. Patients and their families that used to cling to their doctors and plead for help now independently search papers and find new drugs in the clinical trials database, Clinicaltrial.gov. If a drug approved in Korea is stuck in the reimbursement process, civil complaint emails and calls pour into the webpages and offices of relevant ministries including the National Health Insurance Service and the Ministry of Health and Welfare. The same goes for the pharmaceutical companies that supply the new drugs. Some have described that the complaints have been "hindering work to the point of paralysis." The magnitude of the anger in the patients and their families looking at ‘existent but unreachable drugs’ are not so different from before. However, the current generation, which consists of a larger proportion of highly educated people, has ‘administrative power.’ The rising voice has reached the National Assembly. The NA questioned and criticized the Ministry of Health and Welfare and its affiliated agencies (HIRA, NHIS) in their audit. Professional terms related to reimbursement, such as the pharmacoeconomic evaluation exemption system, ICER value, and Cancer Disease Review Committee, are also commonly mentioned. Pressure from the National Assembly and patients, not from pharmaceutical companies, is imposing an incomparable weight on the health authorities. It will also inevitably affect the reimbursement listing process. The PA and GA managers at pharmaceutical companies focus on handling issues arising from these situations. This is why the government often accuses pharmaceutical companies of triggering this phenomenon. In a way, it is a reasonable doubt. When sharing the same interest, patients can work as the best weapon for pharmaceutical companies. Also, the accusations are not 100% false. Some companies use patient groups to raise public opinion and criticize the government. In addition, there are companies that drop the introduction of some drugs due to lack of marketability in Korea despite public criticism, and companies that deliberately delay drug price negotiations to be included in the government’s coverage enhancement plan. They all do exist. However, patients are now a 'double-edged sword' for the companies as well. Patients are moving faster than the listing plan set by the companies after approval, and the reimbursement standards the company sets through discussion with the authorities arouse impatience and anger amongst ineligible patients. The PA and GA meet with the National Assembly and patients to explain, clarify issues, and discuss support plans. Due to the highly sensitive nature of the work, education is essential to avoid crossing the line. One thing clear is that the position was created due to the prevailing trend, even more so than for the company’s pursuit of profit. A PA official at a multinational pharmaceutical company said, "Even support programs for non-reimbursed treatments are also required to abide by the Fair Trade Act. Although people may suspect that we have alternative purposes, I believe everyone will feel the same way when they meet actual patients and their families. There are times I clash with the company due to such effect.” The official added, “Among the issues patient organizations always raise, there are many opinions that the government (especially the MOHW) should prepare an official communication channel (with dedicated personnel and departments) for patients and implement a system that regularly and continuously holds an ear out to the patients' voices. It is now the time for both the government and the pharmaceutical industry to accept the patients’ request." ◆Drug become better and more expensive, system’s scope narrows=Patients that were incurable in the past are now allowed to live their life with the benefit of a drug and even dream of a cure. Advanced cutting-edge new drugs we encounter now offer surprising efficacy and safety. In addition to one-shot CAR-T therapies, approvals for new drugs with various mechanisms of action such as targeted anticancer drugs, cancer immunotherapies, and ADCs, as well as new drugs applied to specific targets or all-comers are lining up their applications. Korea’s reimbursement system has also evolved. Institutional devices for the introduction of high-priced new drugs, such as the Risk Sharing Agreement (RSA) scheme and pharmacoeconomic evaluation exemption system have been prepared, and many drugs have been listed with reimbursement thanks to such systems. Nonetheless, the current system seems too narrow to accommodate these rising new drugs. Although the companies applied for reimbursement listing, more and more drugs remain in the discussion stage for 1 to even 3 years at most. Also, the rejection rate in the CDDC stage, which is an essential gateway to reimbursement for anticancer drugs, has peaked. A study found that 76% of respondents in the industry pointed to the expansion of the RSA system and the separation of the refund-type RSA as ways to improve the current insurance reimbursement system, and 16% answered that the reimbursement listing system needed fundamental improvement. In other words, an increasing number of pharmaceutical companies are looking to change the reimbursement system to list their new drugs, rather than finding a way within the system. GAs play a pivotal role in this context. If the MA appeals to the MOHW, NHIS, and HIRA on the need for a drug, GAs play a broader role in drawing a public picture. This is also the reason why an increasing number of GAs in the industry are former NA aides. However, internal and external conflicts still remain. Internally, MAs, who are typically pharmaceutical industry experts, have a good understanding of drugs and the drug pricing system, but GAs are often not from the pharmaceutical industry. In other words, the perception that 'GAs don't know the industry well' exists in compnaies. One manager explained that internal disputes arise between the MA that speaks on behalf of HIRA, and the GA that speaks on behalf of the NA. A GA manager from a multinational company said, "I feel most upset when people mistakenly believe that I’m not working because I have to work outside the office to meet various people. Pharmaceutical companies also follow the trend and communicate better internally. Only pharmaceutical companies that can create synergy with various internal departments can succeed in leveraging GA. Integrate the internal message first to progress further."
- Opinion
- [Reporter's View] Preferential price for innovative drugs
- by Lee, Jeong-Hwan Apr 06, 2023 05:54am
- Second Vice Minister of Health and Welfare Park Min-soo promised the National Assembly that he would make a rule that gives preferential prices to medicines made by innovative pharmaceutical companies over other medicines. This is in the same context as Vice Minister Park Min-soo clearly expressed his will to improve the drug pricing system, which includes specific drug price preferential treatment for innovative new drugs and essential drugs, at a meeting of the Ministry of Health and Welfare's press conference in February. Last month, at the Health and Welfare Committee of the National Assembly, Vice Minister Park asked that the preferential treatment policy for innovative drugs be made clear so that the mandatory drug price preferential legislation proposed by Rep. Seo Jeong-sook of the People’s Power of Innovative pharmaceutical companies should not be passed and the review suspended. To borrow the expression at the time, Vice Minister Park said, "(Within the Pharmaceutical Industry Promotion and Support Special Act), we will materialize the presidential decree and prepare a policy plan to improve the health insurance drug price system. Please keep an eye on it. Legislation of compulsory regulations is burdensome." When inquiries from Rep. Seo Jeong-sook, who proposed a bill to enforce preferential drug pricing in the 21st National Assembly, and Democratic Party lawmaker Nam In-soon, who first proposed a bill for voluntary drug price preferential treatment in the 20th National Assembly, Vice Minister Park stopped the legislation and confirmed the implementation of the policy. am. It is noteworthy that Vice Minister Park's promise to enact lower-level laws is in stark contrast to the Ministry of Health and Welfare's passive attitude in making lower-level laws, citing trade frictions. However, it is regrettable that Vice-Minister Park did not suggest a specific timing for establishing a preferential drug price policy. Even now, it should have set the exact time when the policy will be made and released so that it can be free from criticism that the enactment of the lower statute is very slow. In November 2018, the government promulgated legislation on preferential drug prices, including the addition of the upper limit on drugs manufactured by innovative pharmaceutical companies, after passing the plenary session of the National Assembly. However, even after four years, it is evaluated that the work of enacting sub-laws to support the effectiveness of drug price preferential treatment has not progressed forward. This is the background of Congressman Seo, who sympathized with the long wait and frustration of the pharmaceutical industry and introduced a bill to change the voluntary drug price preferential regulation into a compulsory regulation. The expert committee of the Welfare Committee also supported Congressman Seo's bill with the intention that the legislation was not unreasonable and the necessity and legitimacy were recognized. There was a movement for a sub-decree. In October 2021, the Ministry of Health and Welfare through the Korea Health Industry Development Institute ordered a 'research on drug price support policies for innovative pharmaceutical companies that conform to the international trade order'. However, even in this study, the original plan to announce the research results in May 2022 was not properly followed, and the vacuum in the lower statute has been walking in place so far. This is the reason why Rep. Seo and Rep. Nam did not hide their suspicious suspicions from Vice Minister Park, who revealed his will to legislate the rule of preferential drug pricing without fail. Fortunately, this time, along with the expression of Vice Minister Park's will, the Ministry of Health and Welfare's movement to enact substantive sub-statutes is accompanied by an atmosphere. The Ministry of Health and Welfare, along with NHIS, HIRA, and three pharmaceutical organizations, supervised a public-private consultative body to improve the drug price system. Vice Minister Park said, “Even if the law is changed to a mandatory regulation to prepare a preferential drug price clause, there is no problem when the Ministry of Health and Welfare does not comply with it, so it is ineffective.” It was explained that if the government's will and policy direction were firm, it could create a preferential treatment plan without amending the law. As the Ministry of Health and Welfare has virtually ended the work of collecting opinions from domestic and foreign pharmaceutical companies and bio companies, Vice Minister Park believes that he must directly roll up his sleeves and take the lead so that specific drug price preferential regulations can be completely unveiled at least within the first half of this year. If the enactment of sub-statutes is postponed again without a promise in the face of the temporary suspension of the National Assembly legislation, it will be difficult to be free from criticism that the Ministry of Health and Welfare is taking the legislative branch lightly. It is hoped that the enactment of the sub-statute by the Ministry of Health and Welfare will eliminate the need for review by the National Assembly for the enforcement of preferential drug price regulations ahead of the midsummer heat wave that will be approaching this year without fail. In addition, it is hoped that the sub-laws to be enacted will be filled with effective content to quench the thirst of the pharmaceutical industry, which has been waiting for five years and repeatedly complaining. It is important to carefully reflect on the preferential provisions that the industry really wants, not the formal administration of the National Assembly in preparing a plan for preferential drug prices. In order to nurture the biopharmaceutical industry and realize the creation of global blockbuster domestically produced new drugs, it is possible to achieve economic effects as well as realize policy goals by establishing sincere preferential measures by listening to the opinions of the industry.
